Opioid Receptor Delta 1 (OPRD1) ACTOne Stable Cell Line
|
Catalog Number:
CL-11-OPRD1
|
|
In Stock
|
Price: Please inquire order@eEnzyme.com
Detailed Description
|
CL-11-OPRD1
|
|
Name
|
Opioid Receptor Delta 1 (OPRD1) ACTOneTM Stable Cells |
|
Description
|
This cell line is a HEK-293-CNG cell line that expresses a recombinant human OPRD1. HEK-293-CNG cells express a modified CNG (Cyclic Nucleotide Gated) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization. The assay allows both end-point and kinetic measurement of intracellular cAMP changes with a FDSS, FLIPR, or a fluorescence microplate reader.
|
|
Application
|
cAMP dependent assay for Gi-coupled human OPRD1;
Cell-based high-throughput screening of human OPRD1 agonists/antagonists.
|
|
Size
|
1x 106 cells
|
|
Detection
|
FlexStation or Microplate reader
|
|
For Downloading
|
==>> DATA SHEET ==>> MSDS
|
Synonym: Delta-Type Opioid Receptor, D-OR-1, DOR-1, OPRD, Opioid Receptor Delta 1, Delta Opioid Receptor 1, DOR1, DOP, DOR
About Human Delta Opioid Receptor (OPRD1/DOR) Stable Cell Line
Delta Opioid Receptor (OPRD1), also known as the δ-opioid receptor (DOR), is a Class A G protein-coupled receptor (GPCR) that is activated primarily by the endogenous opioid peptides Met-enkephalin and Leu-enkephalin. OPRD1 predominantly couples to Gi/o proteins, resulting in inhibition of adenylate cyclase activity, reduced intracellular cAMP production, modulation of calcium and potassium channels, and decreased neuronal excitability. The receptor is widely expressed throughout the brain, spinal cord, and peripheral nervous system, where it regulates pain perception, mood, emotional responses, and neurotransmitter release.
OPRD1 has emerged as an important therapeutic target for pain management, depression, anxiety, migraine, epilepsy, and substance use disorders. Compared with μ-opioid receptor agonists, selective δ-opioid receptor agonists have attracted considerable interest because they may provide analgesic and antidepressant effects with a lower risk of respiratory depression and dependence.
eEnzyme's Human OPRD1 Stable Cell Line provides a reliable platform for investigating DOR-mediated signaling and evaluating agonists, antagonists, and novel receptor modulators using cAMP and other GPCR functional assays. The cell line is well suited for receptor characterization, compound profiling, potency determination, and high-throughput drug screening.
Applications
• OPRD1 (DOR) receptor pharmacology studies
• Opioid signaling research
• Agonist and antagonist screening
• Pain and analgesic drug discovery
• Depression and anxiety research
• Addiction and substance use disorder studies
• cAMP and GPCR functional assays
• High-throughput screening (HTS)
Biological Significance of OPRD1
OPRD1 is a key regulator of opioid signaling in both the central and peripheral nervous systems. Activation of the receptor inhibits intracellular cAMP through Gi/o-mediated signaling, suppresses neurotransmitter release, and modulates nociception, mood, emotional behavior, and stress responses. In addition to its well-established role in analgesia, increasing evidence suggests that OPRD1 contributes to antidepressant responses, neuroprotection, and the development of opioid tolerance. Consequently, selective modulation of OPRD1 has become an important strategy for developing safer analgesics and novel therapies for chronic pain, mood disorders, migraine, and addiction. The OPRD1 Stable Cell Line provides a valuable tool for studying opioid receptor biology and accelerating the discovery of next-generation therapeutics targeting δ-opioid receptor signaling.
|
|
|